Document is current
Any future updates will be listed below
-
Authors
Fahed, Akl C.
Wang, Minxian https://orcid.org/0000-0002-3753-508X
Homburger, Julian R.
Patel, Aniruddh P. https://orcid.org/0000-0001-7871-9638
Bick, Alexander G.
Neben, Cynthia L.
Lai, Carmen
Brockman, Deanna
Philippakis, Anthony
Ellinor, Patrick T.
Cassa, Christopher A.
Lebo, Matthew https://orcid.org/0000-0002-9733-5207
Ng, Kenney https://orcid.org/0000-0003-0792-070X
Lander, Eric S.
Zhou, Alicia Y.
Kathiresan, Sekar https://orcid.org/0000-0002-6724-032X
Khera, Amit V.
- License Information
-
More Information
Article History
Received: 20 February 2020
Accepted: 22 June 2020
First Online: 20 August 2020
Competing interests
: A.C.F. is a consultant and holds equity in Goodpath. J.R.H., C.L.N., C.L., and A.Y.Z. are employees of Color Genomics. A.P. is a Venture Partner at GV, a subsidiary of Alphabet Corporation. P.T.E. is supported by a grant from Bayer AG to the Broad Institute focused on the genetics and therapeutics of cardiovascular diseases, and has served on advisory boards or consulted for Bayer AG, Quest Diagnostics, and Novartis. K.N. is an employee of IBM Research. E.S.L. serves on the Board of Directors for Codiak; serves on the Scientific Advisory Board of F-Prime Capital Partners and Third Rock Ventures; serves on the Board of Directors of the Innocence Project, Count Me In, and Biden Cancer Initiative; and serves on the Board of Trustees for the Parker Institute for Cancer Immunotherapy. S.K. is an employee of Verve Therapeutics, and holds equity in Verve Therapeutics, Maze Therapeutics, Catabasis, and San Therapeutics. He is a member of the scientific advisory boards for Regeneron Genetics Center and Corvidia Therapeutics; he has served as a consultant for Acceleron, Eli Lilly, Novartis, Merck, Novo Nordisk, Novo Ventures, Ionis, Alnylam, Aegerion, Haug Partners, Noble Insights, Leerink Partners, Bayer Healthcare, Illumina, Color Genomics, MedGenome, Quest, and Medscape; he reports patents related to a method of identifying and treating a person having a predisposition to or afflicted with cardiometabolic disease (20180010185) and a genetics risk predictor (20190017119). A.V.K. has served as a consultant to Sanofi, Medicines Company, Maze Pharmaceuticals, Navitor Pharmaceuticals, Verve Therapeutics, Amgen, and Color Genomics; received speaking fees from Illumina, the Novartis Institute for Biomedical Research; received sponsored research agreements from the Novartis Institute for Biomedical Research and IBM Research, and reports a patent related to a genetic risk predictor (20190017119). The remaining authors have no disclosures.
